Dr. Robert Jones

Anesthesiology
Office
4242 Medical Dr Ste 1300, 
San Antonio, TX 
Office
4242 Medical Dr Ste 1300, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Jones is an Anesthesiologist in San Antonio, Texas. His top areas of expertise are Febrile Neutropenia, Orchiectomy, and Nephrectomy.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Anesthesiology
Licenses
Anesthesiology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
4242 Medical Dr Ste 1300, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: AZD5363, Fulvestrant
Study Phase: Phase 1/Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease
[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease
Enrollment Status: Withdrawn
Publish Date: April 01, 2022
Intervention Type: Device
Study Phase: Not Applicable
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Enrollment Status: Terminated
Publish Date: March 10, 2022
Intervention Type: Biological
Study Phase: Phase 2
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer
NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer
Enrollment Status: Completed
Publish Date: July 29, 2020
Intervention Type: Device
View 10 Less Clinical Trials

175 Total Publications

Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2025
Similar Doctors
Expertise in
1
conditions
Dr. Brandon Bregman
Anesthesiology
Expertise in
1
conditions
Dr. Brandon Bregman
Anesthesiology

Northwest Anesthesiology SA P.A.

45 NE Loop 410 Ste 900, 
San Antonio, TX 
 (5.1 miles away)
210-413-2932
Languages Spoken:
English
See accepted insurances

Brandon Bregman is an Anesthesiologist in San Antonio, Texas. Dr. Bregman is highly rated in 1 condition, according to our data. His top area of expertise is Ptosis.

Expertise in
4
conditions
Dr. Jerome J. Aul
Anesthesiology
Expertise in
4
conditions
Dr. Jerome J. Aul
Anesthesiology

Emergenchealth PLLC

11212 State Hwy 151, 
San Antonio, TX 
 (8.4 miles away)
210-703-8801
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jerome Aul is an Anesthesiologist in San Antonio, Texas. Dr. Aul is highly rated in 4 conditions, according to our data. His top areas of expertise are Sacroiliac Joint Disease, Phantom Limb Pain, Fractured Spine, Opioid Induced Constipation, and Ureteroscopy. Dr. Aul is currently accepting new patients.

Expertise in
3
conditions
Dr. Liliana Meskill
Anesthesiology
Expertise in
3
conditions
Dr. Liliana Meskill
Anesthesiology

Office

5364 Fredericksburg Rd Ste 100, 
San Antonio, TX 
 (0.8 miles away)
210-441-4330
Languages Spoken:
English
See accepted insurances

Liliana Meskill is an Anesthesiologist in San Antonio, Texas. Dr. Meskill is highly rated in 3 conditions, according to our data. Her top areas of expertise are Chronic Pain, Sacroiliac Joint Disease, Herniated Disk, and Cervical Spondylosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jones's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile